

Facile Synthesis of 2-Alkynyloxazoles *via* Ce(OTf)₃-Catalyzed Cascade Reaction of Alkynyl Carboxylic Acids with *tert*-Butyl Isocyanide

Ming Cao,^{+a} Qing-Hu Teng,^{+b} Zhi-Wei Xi,^a Li-Qiu Liu,^a Ren-Yong Gu^{*a} and Ying-Chun Wang^{*a}

- ^a National Demonstration Center for Experimental Chemistry Education, Hunan Engineering Laboratory for Analyse and Drugs Development of Ethnomedicine in Wuling Mountains, Jishou University, Jishou 416000, P. R. China
E-mail: wangyingchunjsu@163.com; gry8565398@163.com
- ^b School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, People's Republic of China

Table of Contents

Experimental.....	S2
General methods and materials.....	S2
General procedure for the synthesis of 2-alkynyloxazoles 2a.....	S2
Procedure of anticancer activity assay.....	S2-S3
Table S1 Effect of compounds 2a-v against cell viability of different cell lines ..	S3
HRMS analysis of [¹⁸O₂]-2'a.....	S4
X-ray data for compound 2s.....	S4-S5
X-ray data for compound 3a.....	S5-S6
Spectral data of all compounds.....	S6-S14
Copies of ¹H NMR and ¹³C NMR spectra of all compounds.....	S15-S40

Experimental

General methods and materials. Proton nuclear magnetic resonance spectra (^1H NMR) and carbon nuclear magnetic resonance spectra (^{13}C NMR) were recorded at 400 MHz and 100 MHz or 500 MHz and 125 MHz, respectively, using CDCl_3 as reference standard (δ 7.26 ppm) for ^1H NMR and (δ 77.04 ppm) for ^{13}C NMR. HRMS were recorded using ESI. Melting points were uncorrected. Precoated silica gel plates F-254 were used for analytical thin-layer chromatography. Column chromatography was performed on silica gel (300-400 mesh). Starting material alkynyl carboxylic acids were readily prepared according to literature procedures. Unless otherwise noted, all reagents were obtained commercially and used without further purification.

General procedure for the synthesis of 2-alkynyloxazole 2a.



A mixture of phenylpropionic acid **1a** (1.0 equiv, 0.5 mmol), *tert*-butyl isocyanide (3.0 equiv, 1.5 mmol), $\text{Ce}(\text{OTf})_3$ (10 mol%, 0.05 mmol) and 2 mL of toluene was stirred at 60 °C for 1 h. The progress of the reaction was monitored by thin-layer chromatography. After the reaction was complete, the reaction mixture was subjected to column chromatographic separation (petroleum ether/ethyl acetate) to afford 2-alkynyloxazole **2a**.

Procedure of anticancer activity assay.

The MGC-803, T-24, Hep-G2 and A549 cell lines used in this study were all obtained from the Institute of Biochemistry and Cell Biology, China Academy of Sciences. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) or RPMI-1640, which supplemented with 10% fetal bovine serum in a humidified atmosphere of 5% CO_2 /95% air at 37 °C. The 180 μL cell suspensions (4500-5000 cells/mL) was seeded


in 96-well plates and incubated for 24 h. All compounds and 5-FU were dissolved in the Phosphate Buffered Saline (PBS) with 1% DMSO to give various concentrations (2.5, 5, 10, 20, 40 μ M, respectively) to 96-well plates and control wells contained supplemented media with 1% DMSO. Continue incubating for 48 h at 37 °C and in 5% CO₂ atmosphere and then the MTT solution (10 μ L, 5 mg/mL) was added into each well and the cultures were incubated further for 4~6 h. After removal of the supernatant, DMSO (100 μ L) was added to dissolve the formazan crystals. The absorbance was read by enzyme labeling instrument with 570/630 nm double wavelength measurement. The cytotoxicity was estimated based on the percentage cell survival in a dose dependent manner relative to the negative control. The final IC₅₀ (a drug concentration killing 50% cells) values were calculated by the Bliss method (n $\geq$ 5). All the tests were repeated in at least three independent experiments.

Table S1 Effect of compounds 2a-v against cell viability of different cell lines^a

Compound	IC ₅₀ $\pm$ SD (μ M) ^a			
	MGC803	T24	HepG2	A549
2a	35.49 $\pm$ 1.14	26.33 $\pm$ 0.46	28.44 $\pm$ 0.31	57.23 $\pm$ 0.73
2b	17.88 $\pm$ 1.7	11.56 $\pm$ 0.09	27.34 $\pm$ 0.37	24.01 $\pm$ 1.22
2c	77.46 $\pm$ 0.68	27.52 $\pm$ 2.93	89.93 $\pm$ 2.31	44.52 $\pm$ 4.02
2d	28.96 $\pm$ 1.28	29.17 $\pm$ 2.43	31.05 $\pm$ 0.75	28.36 $\pm$ 0.81
2e	27.22 $\pm$ 2.69	34.69 $\pm$ 2.54	35.79 $\pm$ 0.59	54.79 $\pm$ 1.61
2f	49.43 $\pm$ 3.02	21.44 $\pm$ 0.86	59.20 $\pm$ 0.4	50.17 $\pm$ 0.9
2g	84.64 $\pm$ 2.21	32.61 $\pm$ 1.45	21.93 $\pm$ 0.61	39.40 $\pm$ 0.37
2h	16.86 $\pm$ 1.37	32.94 $\pm$ 1.03	29.32 $\pm$ 0.55	28.69 $\pm$ 0.91
2i	100.98 $\pm$ 1.56	50.50 $\pm$ 2.32	45.87 $\pm$ 0.93	25.53 $\pm$ 1.24
2j	40.78 $\pm$ 2.16	80.51 $\pm$ 0.71	25.84 $\pm$ 1.92	44.50 $\pm$ 1.16
2k	15.61 $\pm$ 1.96	29.54 $\pm$ 0.97	24.80 $\pm$ 2.61	42.53 $\pm$ 1.22
2m	48.10 $\pm$ 2.12	62.12 $\pm$ 0.77	41.15 $\pm$ 0.36	59.10 $\pm$ 2.14
2n	15.92 $\pm$ 1.24	50.86 $\pm$ 2.62	59.95 $\pm$ 0.39	45.36 $\pm$ 0.67
2o	20.26 $\pm$ 1.54	73.22 $\pm$ 2.43	28.00 $\pm$ 1.17	80.70 $\pm$ 0.46
2p	19.69 $\pm$ 1.09	62.12 $\pm$ 3.04	50.38 $\pm$ 1.27	58.79 $\pm$ 0.27
2q	55.50 $\pm$ 2.03	65.76 $\pm$ 1.72	27.73 $\pm$ 1.35	53.62 $\pm$ 0.94
2s	57.13 $\pm$ 2.11	56.76 $\pm$ 0.78	30.06 $\pm$ 1.45	43.72 $\pm$ 0.79
2t	18.67 $\pm$ 1.15	34.84 $\pm$ 1.11	39.33 $\pm$ 1.96	43.83 $\pm$ 0.93
2v	45.49 $\pm$ 2.03	40.48 $\pm$ 1.74	20.10 $\pm$ 0.82	23.82 $\pm$ 1.03
5-FU	45.76 $\pm$ 1.97	40.14 $\pm$ 2.14	23.60 $\pm$ 2.11	34.32 $\pm$ 2.19

^a IC₅₀ (μ mol L⁻¹) values are presented as the mean $\pm$ SD (standard error of the mean) from the three separate experiments; 5-FU: 5-fluorouracil.

HRMS analysis of [¹⁸O₂]-2'a



X-ray data for compound 2s





Table S2 Crystal data and structure refinement for 2s

Compound	2s
Empirical formula	C ₁₈ H ₂₃ N ₃ O ₂ S
Formula weight	345.45
Temperature/K	100.00(10)
Crystal system	monoclinic
Space group	P2 ₁ /n
a/Å	11.6688(3)

b/Å	10.6008(3)
c/Å	31.1741(9)
$\alpha/^\circ$	90
$\beta/^\circ$	100.107(3)
$\gamma/^\circ$	90
Volume/Å ³	3796.35(19)
Z	8
$\rho_{\text{calc}}/\text{cm}^3$	1.209
μ/mm^{-1}	1.629
F(000)	1472.0
Crystal size/mm ³	0.13 × 0.12 × 0.11
Radiation	CuK α (λ = 1.54184)
2 Θ range for data collection/ $^\circ$	5.76 to 147.504
Index ranges	-14 ≤ h ≤ 10, -7 ≤ k ≤ 13, -38 ≤ l ≤ 38
Reflections collected	14668
Independent reflections	7409 [R_{int} = 0.0356, R_{sigma} = 0.0445]
Data/restraints/parameters	7409/8/471
Goodness-of-fit on F^2	1.038
Final R indexes [$I \geq 2\sigma(I)$]	R_1 = 0.0564, wR_2 = 0.1439
Final R indexes [all data]	R_1 = 0.0638, wR_2 = 0.1515
Largest diff. peak/hole / e Å ⁻³	0.52/-0.40

X-ray data for compound 3a




3a

Table S3 Crystal data and structure refinement for 3a

Compound	3a
Empirical formula	C ₂₇ H ₃₈ N ₆ O ₂
Formula weight	478.63
Temperature/K	100.00(10)
Crystal system	orthorhombic
Space group	Pbca


a/Å	19.2320(3)
b/Å	11.92476(17)
c/Å	23.5435(4)
$\alpha/^\circ$	90
$\beta/^\circ$	90
$\gamma/^\circ$	90
Volume/Å ³	5399.40(15)
Z	8
$\rho_{\text{calc}}/\text{cm}^3$	1.178
μ/mm^{-1}	0.607
F(000)	2064.0
Crystal size/mm ³	0.12 × 0.11 × 0.1
Radiation	Cu K α (λ = 1.54184)
2 Θ range for data collection/ $^\circ$	7.51 to 147.242
Index ranges	-22 ≤ h ≤ 23, -11 ≤ k ≤ 14, -29 ≤ l ≤ 27
Reflections collected	14096
Independent reflections	5342 [R_{int} = 0.0358, R_{sigma} = 0.0400]
Data/restraints/parameters	5342/0/322
Goodness-of-fit on F ²	1.037
Final R indexes [$I \geq 2\sigma(I)$]	R_1 = 0.0435, wR_2 = 0.1067
Final R indexes [all data]	R_1 = 0.0540, wR_2 = 0.1146
Largest diff. peak/hole / e Å ⁻³	0.47/-0.44

Spectral data of all compounds




***N*-tert-butyl-5-(tert-butylamino)-2-(2-phenylethynyl)oxazole-4-carboxamide (2a):** light yellow solid, m.p. 44.2–46.5 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.58 (dd, J = 7.4, 1.6 Hz, 2H), 7.41–7.34 (m, 3H), 6.80 (s, 1H), 6.30 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H)


ppm; ¹³C NMR (100 MHz, CDCl₃): δ 163.2, 157.1, 134.0, 131.9, 129.5, 128.5, 121.0, 107.7, 91.1, 77.2, 52.9, 51.0, 29.9, 29.3 ppm; HRMS (m/z) (ESI): calcd for C₂₀H₂₆O₂N₃ 340.2025 [M+H]⁺; found 340.2012.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(4-ethylphenyl)ethynyl)oxazole-4-carboxamide (2b):** yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.55–7.45 (m, 2H), 7.20 (d, J = 8.3 Hz, 2H), 6.78 (s, 1H), 6.30 (s, 1H), 2.67 (q, J = 7.6 Hz, 2H), 1.44 (s, 9H), 1.43 (s, 9H), 1.24 (t, J = 7.6 Hz, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.2, 157.1, 146.2, 134.2, 131.9, 128.1, 118.1, 107.6, 91.4, 52.9, 51.0, 29.9, 29.3, 28.9, 15.2 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{22}\text{H}_{30}\text{O}_2\text{N}_3$ 368.2338 $[\text{M}+\text{H}]^+$; found 368.2328.



***N*-tert-butyl-5-(tert-butylamino)-2-(2-(4-methoxyphenyl)ethynyl)oxazole-4-carboxamide (2c):** yellow solid, m.p. 47.1–48.8 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.55–7.46 (m, 2H), 6.91–6.86 (m, 2H), 6.76 (s, 1H), 6.29 (s, 1H), 3.83 (s, 3H), 1.44 (s, 9H), 1.42 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.2, 160.6, 157.0, 134.4, 133.6, 114.2, 113.0, 107.6, 91.3, 76.2, 55.4, 52.8, 51.0, 29.9, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{21}\text{H}_{28}\text{O}_3\text{N}_3$ 370.2131 $[\text{M}+\text{H}]^+$; found 370.2119.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(4-pentyloxyphenyl)ethynyl)oxazole-4-carboxamide (2d):** yellow solid, m.p. 43.1–45.5 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.56–7.43 (m, 2H), 6.91–6.81 (m, 2H), 6.76 (s, 1H), 6.29 (s, 1H), 3.97 (t, J = 6.6 Hz, 2H), 1.85–1.73 (m, 2H), 1.50–1.34 (m, 22H), 0.93 (t, J = 7.1 Hz, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.2, 160.2, 157.0, 134.4, 133.6, 114.7, 112.6, 107.6, 91.4, 76.1, 68.16, 52.8, 51.0, 29.9, 29.3, 28.8, 28.2, 22.4, 14.0 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{25}\text{H}_{36}\text{O}_3\text{N}_3$ 426.2757 $[\text{M}+\text{H}]^+$; found 426.2742.



***N*-(*tert*-butyl)-5-(*tert*-butylamino)-2-((4-fluorophenyl)ethynyl)oxazole-4-carboxamide (2e):**

yellow solid, m.p. 47.2–50.1 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.60–7.52 (m, 2H), 7.10–7.03 (m, 2H), 6.81 (s, 1H), 6.29 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H) ppm;


^{13}C NMR (100 MHz, CDCl_3): δ 163.1, 162.2 (d, $^1J_{\text{CF}} = 250$ Hz), 157.13, 134.0 (d, $^3J_{\text{CF}} = 8.0$ Hz), 133.8, 117.2 (d, $^4J_{\text{CF}} = 4.0$ Hz), 116.0 (d, $^2J_{\text{CF}} = 22.0$ Hz), 107.7, 90.0, 77.2, 52.9, 51.0, 29.8, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2\text{N}_3\text{F}$ 358.1931 $[\text{M}+\text{H}]^+$; found 358.1921.



1-*tert*-butyl-5-(*tert*-butylamino)-4-(4-chlorophenyl)pyridin-2(1*H*)-one (2f):

light yellow solid, m.p. 50.1–53.2 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.54–7.47 (m, 2H), 7.39–7.32 (m, 2H), 6.83 (s, 1H), 6.29 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR


(100 MHz, CDCl_3): δ 163.1, 157.2, 135.7, 133.7, 133.0, 129.0, 119.5, 107.8, 90.0, 78.3, 52.9, 51.0, 29.8, 30.0 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2\text{N}_3\text{Cl}$ 374.1635 $[\text{M}+\text{H}]^+$; found 374.1625.




2-(2-(4-bromophenyl)ethynyl)-*N*-*tert*-butyl-5-(*tert*-butylamino)oxazole-4-carboxamide (2g):

yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.59–7.49 (m, 2H), 7.42–7.35 (m, 2H), 6.80 (s, 1H), 6.30 (s, 1H), 1.44 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3):


δ 163.2, 157.2, 133.2, 131.9, 129.5, 128.5, 121.0, 107.7, 91.1, 78.4, 52.9, 51.0, 29.9, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{16}\text{H}_{25}\text{O}_4\text{N}_2$ 309.1814 $[\text{M}+\text{H}]^+$; found 309.1791.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(4-(trifluoromethyl)phenyl)ethynyl)oxazole-4-carboxamide (2h):** yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.69–7.62 (m, 4H), 6.88 (s, 1H), 6.29 (s, 1H), 1.46 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.0, 157.3, 133.4, 132.0, 131.2, 126.5 (q, $J = 272.6$ Hz), 125.5 (q, $J = 4.4$ Hz), 124.9 (q, $J = 1.7$ Hz), 108.0, 89.6, 79.5, 53.0, 51.1, 29.8, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{21}\text{H}_{25}\text{O}_2\text{N}_3\text{F}_3$ 408.1899 $[\text{M}+\text{H}]^+$; found 408.1886.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(4-cyanophenyl)ethynyl)oxazole-4-carboxamide (2i):** yellow solid, m.p. 51.2–53.9 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.66 (s, 4H), 6.92 (s, 1H), 6.29 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 162.9, 157.4, 133.1, 132.2, 132.1, 126.0, 118.2, 112.6, 108.2, 89.4, 81.4, 53.00, 51.1, 29.8, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{21}\text{H}_{25}\text{N}_4\text{O}_2$ 365.1978 $[\text{M}+\text{H}]^+$; found 365.1967.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(4-(methoxycarbonyl)phenyl)ethynyl)oxazole-4-carboxamide (2j):** yellow solid, m.p. 44.2–46.5 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.06–8.00 (m, 2H), 7.66–7.58 (m, 2H), 6.86 (s, 1H), 6.29 (s, 1H), 3.93 (s, 3H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 166.3, 163.0, 157.3, 133.5, 131.7, 130.5, 129.6, 125.6, 108.0, 90.3, 80.0, 53.0, 52.3, 51.1, 29.8, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{22}\text{H}_{28}\text{N}_3\text{O}_4$ 398.2080 $[\text{M}+\text{H}]^+$; found 398.2071.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(o-tolylethynyl)oxazole-4-carboxamide (2k):** light yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.54 (d, $J = 7.6$ Hz, 1H), 7.32–7.16 (m, 3H), 6.79 (s, 1H), 6.31 (s, 1H), 2.52 (s, 3H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.2, 157.1, 141.0, 134.1, 132.3, 129.7, 129.5, 125.7, 120.8, 107.7, 90.1, 80.92, 52.87, 50.99, 29.85, 29.31, 20.65 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{21}\text{H}_{28}\text{O}_2\text{N}_3$ 354.2182 $[\text{M}+\text{H}]^+$; found 354.2171.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(2-fluorophenyl)ethynyl)oxazole-4-carboxamide (2l):** light yellow solid, m.p. 51.1–53.5 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.38–7.32 (m, 2H), 7.29–7.25 (m, 1H), 7.14–7.06 (m, 1H), 6.84 (s, 1H), 6.29 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 163.13, 162.9 (d, $^1J_{\text{CF}} = 253$ Hz), 157.2, 133.6, 131.3 (d, $^3J_{\text{CF}} = 8.0$ Hz), 124.1 (d, $^4J_{\text{CF}} = 4.0$ Hz), 115.8 (d, $^2J_{\text{CF}} = 20.0$ Hz), 109.9, 107.8, 84.6, 82.0, 78.1, 52.9, 51.0, 29.8, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2\text{N}_3\text{F}$ 358.1931 $[\text{M}+\text{H}]^+$; found 358.1921.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(2-chlorophenyl)ethynyl)oxazole-4-carboxamide (2m):** light yellow solid, m.p. 53.2–55.7 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.60 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.44 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.35–7.26 (m, 2H), 6.83 (s, 1H), 6.32 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.1, 157.3, 136.3, 133.6, 130.4, 129.5, 126.6, 121.3, 107.9, 87.7, 82.0, 52.9, 51.0, 29.8, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2\text{N}_3\text{Cl}$ 374.1635 $[\text{M}+\text{H}]^+$; found 374.1625.



***N*-tert-butyl-5-(tert-butylamino)-2-(2-m-tolylethynyl)oxazole-4-carboxamide (2n):** light yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.42–7.36 (m, 2H), 7.27–7.19 (m, 2H), 6.79 (s, 1H), 6.30 (s, 1H), 2.36 (s, 3H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 163.2, 157.1, 138.3, 134.1, 132.4, 130.4, 129.0, 128.4, 120.8, 107.7, 91.3, 52.9, 51.0, 29.9, 29.3, 21.2 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{21}\text{H}_{28}\text{O}_2\text{N}_3$ 354.2182 $[\text{M}+\text{H}]^+$; found 354.2169.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(3-methoxyphenyl)ethynyl)oxazole-4-carboxamide (2o):** light yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.29–7.25 (m, 1H), 7.18 (dt, $J = 7.6, 1.1$ Hz, 1H), 7.10–7.09 (m, 1H), 6.95 (ddd, $J = 8.3, 2.6, 0.9$ Hz, 1H), 6.81 (s, 1H), 6.30 (s, 1H), 3.82 (s, 3H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.2, 159.4, 157.1, 134.0, 129.6, 124.4, 122.0, 116.5, 116.3, 107.7, 91.0, 77.1, 55.4, 52.9, 51.0, 29.9, 29.3 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{21}\text{H}_{28}\text{O}_3\text{N}_3$ 370.2131 $[\text{M}+\text{H}]^+$; found 370.2119.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(3-fluorophenyl)ethynyl)oxazole-4-carboxamide (2p):** yellow solid, m.p. 53.4–56.5 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.38–7.30 (m, 2H), 7.28–7.25 (m, 1H), 7.13–7.06 (m, 1H), 6.84 (s, 1H), 6.29 (s, 1H), 1.45 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.1, 162.3 (d, $^1J_{\text{CF}} = 246.0$ Hz), 157.2, 133.6, 130.2 (d, $^3J_{\text{CF}} = 9.0$ Hz), 127.7 (d, $^4J_{\text{CF}} = 4.0$ Hz), 122.9 (d, $^3J_{\text{CF}} = 10.0$ Hz), 118.6 (d, $^2J_{\text{CF}} = 23.0$ Hz), 117.9 (d, $^2J_{\text{CF}} = 21.0$ Hz), 107.8, 89.7, 78.1, 52.9,

51.0, 29.8, 29.3 ppm; **HRMS** (m/z) (ESI): calcd for $C_{20}H_{25}O_2N_3F$ 358.1931 $[M+H]^+$; found 358.1921.




2-([1,1'-biphenyl]-4-ylethynyl)-*N*-(*tert*-butyl)-5-(*tert*-butylamino)oxazole-4-carboxamide (2q): yellow solid, m.p. 47.5–49.8 °C; 1H NMR (400 MHz, $CDCl_3$): δ 7.64–7.59 (m, 5H), 7.49–7.35 (m, 4H), 6.82 (s, 1H), 6.31 (s, 1H), 1.46 (s, 9H), 1.44 (s, 9H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$): δ 163.2,

157.2, 142.2, 140.0, 134.1, 132.3, 128.9, 128.0, 127.2, 127.2, 119.8, 107.7, 91.1, 78.0, 52.9, 51.0, 29.9, 29.3 ppm; **HRMS** (m/z) (ESI): calcd for $C_{26}H_{30}O_2N_3$ 416.2338 $[M+H]^+$; found 416.2328.



***N*-*tert*-butyl-5-(*tert*-butylamino)-2-(2-(naphthalen-2-yl)ethynyl)oxazole-4-carboxamide (2r):** yellow solid, m.p. 42.3–45.1 °C; 1H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.83 (dd, J = 9.2, 3.4 Hz, 3H), 7.59 (dd, J = 8.5, 1.5 Hz, 1H), 7.55–7.50 (m, 2H),


6.83 (s, 1H), 6.32 (s, 1H), 1.46 (s, 9H), 1.44 (s, 9H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$): δ 163.2, 157.2, 134.1, 133.3, 132.8, 132.4, 128.3, 128.0, 127.9, 127.9, 127.4, 126.9, 118.3, 107.8, 91.6, 77.6, 52.9, 51.0, 29.9, 29.3 ppm; **HRMS** (m/z) (ESI): calcd for $C_{21}H_{28}O_3N_3$ 370.2131 $[M+H]^+$; found 370.2119.




***N*-*tert*-butyl-5-(*tert*-butylamino)-2-(2-(thiophen-3-yl)ethynyl)oxazole-4-carboxamide (2s):** light yellow solid, m.p. 45.3–48.2 °C; 1H NMR (400 MHz, $CDCl_3$): δ 7.65 (dd, J = 3.0, 1.2 Hz, 1H), 7.32 (dd, J = 5.0, 3.0 Hz, 1H), 7.23 (dd, J = 5.0, 1.2 Hz, 1H), 6.79 (s, 1H), 6.29 (s,

1H), 1.44 (s, 9H), 1.43 (s, 9H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$): δ 163.2, 157.1,


134.0, 130.9, 129.7, 125.8, 120.1, 107.6, 86.4, 77.0, 52.9, 51.0, 29.8, 29.3 ppm;
HRMS (m/z) (ESI): calcd for $C_{18}H_{24}O_2N_3S$ 346.1589 $[M+H]^+$; found 346.1578.




***N*-tert-butyl-5-(tert-butylamino)-2-(2-(trimethylsilyl)ethynyl)oxazole-4-carboxamide (2t):** light yellow oil; 1H NMR (400 MHz, $CDCl_3$): δ 6.77 (s, 1H), 6.26 (s, 1H), 1.42 (s, 9H), 1.40 (s, 9H), 0.27 (s, 9H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$): δ 163.6, 157.4, 134.2, 107.8, 98.9, 92.0, 53.4, 51.5, 30.3, 29.8, 0.00 ppm; **HRMS** (m/z) (ESI): calcd for $C_{17}H_{30}O_2N_3Si$ 366.2107 $[M+H]^+$; found 366.2097.



2-(but-1-ynyl)-*N*-tert-butyl-5-(tert-butylamino)oxazole-4-carboxamide (2u): white solid, m.p. 52.6–54.3 °C; 1H NMR (400 MHz, $CDCl_3$): δ 6.66 (s, 1H), 6.25 (s, 1H), 2.45 (q, J = 7.5 Hz, 2H), 1.41 (s, 18H), 1.25 (t, J = 7.5 Hz, 3H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$): δ 163.3, 156.7, 134.2, 107.0, 94.3, 68.4, 52.7, 50.9, 29.9, 29.3, 13.1, 13.0 ppm; **HRMS** (m/z) (ESI): calcd for $C_{16}H_{26}N_3O_2$ 292.2025 $[M+H]^+$; found 292.2014.




***tert*-butyl-5-(tert-butylamino)-2-(hept-1-ynyl)oxazole-4-carboxamide (2v):** yellow oil; 1H NMR (400 MHz, $CDCl_3$): δ 6.66 (s, 1H), 6.25 (s, 1H), 2.43 (t, J = 7.2 Hz, 2H), 1.67–1.59 (m, 2H), 1.47–1.43 (m, 2H), 1.41 (s, 18H), 1.37–1.32 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H) ppm; ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.3, 156.7, 134.3, 106.9, 93.3, 70.0, 52.7, 50.9, 31.1, 29.9, 29.3, 27.7, 22.1, 19.3, 13.9 ppm; **HRMS** (m/z) (ESI): calcd for $C_{19}H_{32}O_2N_3$ 334.2494 $[M+H]^+$; found 334.2484.




***N*-(*tert*-butyl)-5-(*tert*-butylamino)-2-(1-(cyclohexylmethyl)-4-phenyl-1*H*-1,2,3-triazol-5-yl)oxazole-4-carboxamide**

(3a): yellow solid, m.p. 85.1–87.2 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.62 (dd, $J = 7.5, 1.5$ Hz, 2H), 7.42–7.35 (m, 3H), 6.61 (s, 1H), 6.25 (s, 1H), 4.49 (d, $J = 7.1$ Hz, 2H), 1.76–1.67 (m, 6H), 1.45 (s, 9H), 1.29–1.19 (m, 5H), 1.15 (s, 9H) ppm; ^{13}C NMR (100MHz, CDCl_3): δ 163.3, 156.9, 146.7, 138.7, 130.5, 128.6, 128.6, 128.5, 122.0, 108.0, 55.9, 52.7, 51.0, 38.4, 30.5, 29.5, 29.3, 26.2, 25.6 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{27}\text{H}_{39}\text{O}_2\text{N}_6$ 479.3134 $[\text{M}+\text{H}]^+$; found 479.3107.




***N*-*tert*-butyl-5-(*tert*-butylamino)-2-phenyloxazole-4-**

carboxamide (2'a): light yellow solid, m.p. 91.3–93.8 °C (lit.¹ 92–94 °C); ^1H NMR (500 MHz, CDCl_3) δ 7.87 (d, $J = 7.6$ Hz, 2H), 7.39 (dt, $J = 27.5, 6.8$ Hz, 3H), 6.55 (s, 1H), 6.38 (s, 1H), 1.47 (s, 18H) ppm; ^{13}C NMR (125 MHz, CDCl_3): δ 164.0, 157.1, 149.2, 129.2, 128.8, 127.3, 125.1, 108.2, 52.8, 50.9, 30.0, 29.4 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{18}\text{H}_{26}\text{O}_2\text{N}_3$ 316.2020 $[\text{M}+\text{H}]^+$; found 316.2029.



(*E*)-*N*-*tert*-butyl-5-(*tert*-butylamino)-2-styryloxazole-4-

carboxamide (2'b): yellow oil; ^1H NMR (400 MHz, CDCl_3): δ 7.48 (d, $J = 7.4$ Hz, 2H), 7.36 (t, $J = 7.4$ Hz, 2H), 7.32–7.25 (m, 1H), 7.16 (d, $J = 16.3$ Hz, 1H), 6.74 (d, $J = 16.3$ Hz, 1H), 6.66 (s, 1H), 6.28 (s, 1H), 1.47 (s, 9H), 1.45 (s, 9H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 163.8, 156.9, 149.4, 135.9, 132.5, 128.9, 128.6, 126.8, 113.4, 108.4, 52.7, 50.9, 29.9, 29.4 ppm; HRMS (m/z) (ESI): calcd for $\text{C}_{20}\text{H}_{28}\text{O}_2\text{N}_3$ 342.2176 $[\text{M}+\text{H}]^+$; found 342.2186.



***N*,2-di-*tert*-butyl-5-(*tert*-butylamino)oxazole-4-carboxamide**

(2'c): colorless solid, m.p. 67.2–69.7 °C (lit.¹ 68–70 °C); ^1H NMR (500 MHz, CDCl_3): δ 6.28 (s, 1H), 6.25 (s, 1H), 1.46 (s, 9H), 1.40 (s, 9H), 1.35 (s, 9H) ppm; ^{13}C NMR (125 MHz, CDCl_3): δ 164.2, 158.6, 156.9, 106.3, 52.5, 50.7, 33.3, 30.0,

29.4, 28.4 ppm; **HRMS** (m/z) (ESI): calcd for $C_{16}H_{30}O_2N_3$ 296.2333 $[M+H]^+$; found 296.2344.

1. Y. Odabachian, S. Tong, Q. Wang, M.-X. Wang and J.-P. Zhu, *Angew. Chem. Int. Ed.*, 2013, **52**, 10878–10882.

Copies of 1H NMR and ^{13}C NMR spectra of all compounds

